Rubella virus (RUBV) replicons expressing a drug resistance gene and a gene of interest were used to select cell lines uniformly harboring the replicon. Replicons expressing GFP and a virus capsid protein GFP fusion (C-GFP) were compared. Vero or BHK cells transfected with either replicon survived drug selection and grew into a monolayer. However, survival was $ 9-fold greater following transfection with the C-GFP-replicon than with the GFP-expressing replicon and while the C-GFP-replicon cells grew similarly to non-transfected cells, the GFP-replicon cells grew slower. Neither was due to the ability of the CP to enhance RNA synthesis but survival during drug selection was correlated with the ability of CP to inhibit apoptosis. Additionally, C-GFP-replicon cells were not cured of the replicon in the absence of drug selection. Interferon-alpha suppressed replicon RNA and protein synthesis, but did not cure the cells, explaining in part the ability of RUBV to establish persistent infections.
Introduction
Rubella virus (RUBV), the sole member of the Rubivirus genus in the family Togaviridae, is a plus strand RNA virus with a genome of $10 kb that contains two open reading frames (ORF's): the 5 0 proximal ORF or NS-ORF encodes a precursor which is cleaved to produce the two replicase proteins P150 and P90 while the 3 0 proximal ORF or SP-ORF encodes the virion proteins CP (capsid protein), E1 and E2 (envelope glycoproteins) (Frey, 1994) . The NS-ORF is translated from the genome RNA while the SP-ORF is translated from a subgenomic (SG) RNA synthesized in infected cells. By manipulation of a RUBV infectious cDNA clone, monocistronic replicons have been developed in which the SP-ORF is replaced with a foreign gene (Tzeng et al., 2001) . Using an internal ribosome entry site or IRES, bicistronic replicons expressing two foreign genes have also been generated (Fontana et al., 2007; Pugachev et al., 2000) .
In addition to replicons that express a foreign gene in the initially transfected cell (replicons cannot spread from cell to cell without an independent source of virion proteins), replicons expressing a drug resistance gene have been used to select cell cultures that uniformly harbor the replicon (Blight et al., 2000; Frolov et al., 1999; Graff et al., 2006; Liu et al., 2004; Lohmann et al., 2003; Mackenzie et al., 2001; Perri et al., 2000; Pflugheber et al., 2002; Zhu et al., 2003) . Such cell cultures are useful in characterizing the intracellular replication of viruses that multiply poorly in cell culture. RUBV multiplies in a number of standard cell culture lines, but in all cell culture lines tested, RUBV replication is slow and asynchronous and often complete infection of cells in the culture is not achieved, making the virus replication cycle difficult to study (Frey, 1994) . We therefore introduced a drug resistance gene into the RUBV bicistronic replicon for the purpose of selecting uniformly transfected cultures. By using the bicistronic replicon, we were also able to characterize the effect of an independent protein on replicon replication and the phenotype of the transfected cell. For this initial study, we chose the virus CP, a multifunctional protein which in addition to forming the core or nucleocapsid within the virus particle has also been shown to: enhance replicon RNA synthesis (Tzeng et al., 2006) ; modulate genomic and SG RNA synthesis (Tzeng and Frey, 2005) ; rescue a lethal mutation in the replicase gene (Tzeng and Frey, 2003) ; bind to poly A-binding protein blocking translation (Ilkow et al., 2008) , inhibit mitochondrial transport (Ilkow et al., 2010a) , and suppress apoptosis (Ilkow et al., 2011 ) (for review: see (Ilkow et al., 2010c) . Intriguingly, we found that CP enhanced survival of the transfected cells during drug selection and was necessary for the replicon-containing cells to maintain a normal growth rate. In addition, RUBV readily establishes a persistent infection in cell culture (Mifune et al., 1970; Stanwick and Hallum, 1974) and we thus also used the replicon-containing cultures to determine the stability of the replicons and the ability of Type I interferon (IFN) to cure the cells of the replicon, with the intriguing finding that it was unable to do so.
Results

Transfection, drug selection, and properties of drug-selected cell lines
Genomic diagrams of the replicons used in this study are shown in Fig. 1A . In RUBrep/GFP/neo, the SG promoter is followed by the GFP gene, an IRES, and the neomycin resistance gene, while RUBrep/C-GFP/neo contains a C-GFP fusion. The C-GFP fusion in this construct contains all 300 aa of CP. It is to be noted that in our previous studies, only the N-terminal 88 aa of CP were required in the fusion protein to modulate genome and SG RNA synthesis (Tzeng and Frey, 2005) and rescue the P150 NotI deletion mutant (Tzeng and Frey, 2003) .
Vero cells transfected with both replicons were treated with antibiotic G418 four days post-transfection. As shown in Fig. 1B , cells surviving the drug treatment were readily selected, however cell survival was roughly nine times greater in the culture transfected with RUBrep/C-GFP/neo than the culture transfected with RUBrep/ GFP/neo. When both replicons were tested in BHK cells, similar results were obtained as in Vero cells (data not shown), indicating that this cell survival phenomenon was not cell-type specific. In addition, cell survival was also approximately nine times greater in the cultures transfected with the corresponding replicons expressing the puromycin acetylase gene, PAC [RUBrep/C-GFP/PAC and RUBrep/ GFP/PAC, respectively (data not shown)], demonstrating that this cell survival phenomenon was not drug specific as well.
After drug selection and generation of confluent monolayers, cultures transfected with both replicons were subcultured and passed in the presence of antibiotic. As shown in Fig. 1C , the GFP expressed in the RUBrep/GFP/neo-transfected cultures was distributed nonspecifically throughout the cell, including the nucleus, while the C-GFP fusion expressed in the RUBrep/C-GFP cultures had a cytoplasmic distribution with a concentration around the nuclear membrane in the cells with the strongest signal, typical of the distribution of CP in RUBV-infected cells (Frey, 1994) . Interestingly, a higher percentage of the cells in the RUBrep/GFP/neo-transfected cultures ($ 88%) exhibited detectable GFP expression than in the RUBrep/C-GFP/neo-transfected cultures ($ 23%). In addition, to maintain the cultures the RUBrep/GFP/neo cells had to be subcultured at a dilution of ¼ while the RUBrep/C-GFP/neo cells could be subcultured at a dilution of 1/10, similar to routine subculturing of Vero cells. As shown in Fig. 1C , when an equal number of cells were plated (equivalent to subculturing a confluent culture of Vero cells at a dilution of 1/10), the growth rate of the RUBrep/C-GFP/neo cells was similar to that of Vero cells, while the growth rate of the RUBrep/GFP/neo cells was much slower and the cells never reached confluency. When examined by fluorescence activated cell sorting following propidium iodide staining, no differences in the cell cycle distribution were observed between RUBrep/GFP/neo-and RUBrep/C-GFP/neo-transfected cells (analyses were done on days 1 through 4 post-plating, data not shown).
Mechanism behind the difference in cell survival and cell growth
Our initial hypothesis on the mechanism behind the profound effect that CP exerted on survival and growth of the replicon-transfected cultures following selection was that CP mediated more efficient replicon replication and therefore a higher level of neo R gene product given the involvement of CP in virus RNA replication Frey, 2003, 2005) . We therefore analyzed replicon RNA accumulation following transfection up to and at the time of drug selection (days 1 through 4 following transfection) and in transfected cultures after drug selection. As shown in Fig. 2A , replicon RNA accumulation was more rapid in RUBrep/C-GFP/neo-transfected cells than in RUBrep/GFP/neo-transfected cells. However by day 4 post-transfection, the day antibiotic treatment was initiated, the amount of SG RNA was equivalent. As we reported previously (Tzeng and Frey, 2005) , CP modulates an increase in genome RNA production relative to SG RNA production and this effect was evident in that RUBrep/C-GFP/neo produced more genomic RNA than did RUBrep/GFP/neo. As shown in Fig. 2B , in selected cultures the amount of SG RNA in Fig. 2 . Analyses of mechanism of C-mediated cell survival (A) and (B). Replicon-specific RNAs assayed by northern blotting. Total cell RNA was resolved by agarose gel electrophoresis, transferred to nitrocellulose, and probed with 32 P-labeled, nick-translated pGEM/GFP (a plasmid containing the GFP gene). The genomic (G) and SG RNAs are indicated (it is to be noted that these vary in size between different replicons). Shown in (A). is RNA isolated from cells on days 1-4 post-transfection with RUBrep/GFP/ neo or RUBrep/C-GFP/neo. Shown in (B) is RNA isolated from cells transfected with the same replicons on day 4 post-transfection, after 2 weeks of drug-selection, or after 26 weeks maintenance in the presence of G418 (RNA from both a population and a clonally derived line are shown). (C) Neo R factor assayed by Western blotting. Cell lysates were resolved by SDS-PAGE, transferred to nitrocellulose and probed with antibodies against the neo R factor or calnexin (as a loading control). Lysates were from mock-transfected Vero cells, RUBrep/GFP/neo and RUBrep/C-GFP/neo-transfected Vero cells at 2 and 4 days post-transfection or after selection and maintenance in the presence of G418 for 26 weeks. (D) Reverse plaque assay of Vero cells transfected with RUBrep/C(-S)GFP/neo or RUBrep/C-GFP/neo followed by selection with G418. The C(-S)GFP construct (see Fig. 1 ) contains aa 1-277 of C, ie lacking the C-terminal 23 aa which serve as the signal sequence for E2.
RUBrep/GFP/neo-and RUBrep/C-GFP/neo cells was also equivalent, even in cultures maintained for 26 weeks after selection. The characteristic phenotypic ratios of genomic/SG RNA characteristic for each replicon were maintained in selected cultures over this time period and alterations in the replicon RNAs, such as deletions or generation of DI RNAs, were not apparent. We also measured the amount of neo R gene product in transfected cells. As shown in Fig. 2C , at day 2 transfection more neo R gene product was present in RUBrep/ C-GFP/neo-transfected cells than in RUBrep/GFP/neo-transfected cells, consistent with the greater abundance of replicon RNA in the former cells. But by day 4 post-transfection, the day of antibiotic treatment, the amount of neo R gene product was equivalent in the two cultures. Similarly, the amount of neo R gene product was equivalent in cultures following selection. Therefore, our hypothesis that the effect of CP on cell survival and growth under drug selection was mediated at the level of efficiency of replicon replication did not appear to be correct.
We next took a genetic approach to confirm that replicon RNA synthesis was unrelated to cell survival after drug selection by additionally constructing replicons expressing progressive C-terminal deletions of CP fused with GFP. We published previously Frey, 2003, 2005 ) that a fusion consisting of the N-terminal 88 residues of CP fused with GFP is sufficient to rescue P150 mutants with the NotI deletion and modulate the ratio of genomic/SG RNA synthesis. As shown in Fig. 2D , survival of cells transfected with the first replicon in this series, one expressing a fusion protein consisting of the residue 1-277 of CP (lacking the E2 signal sequence) fused with GFP ( Fig. 1A) , was $9 fold lower than cells transfected with the RUBrep/C-GFP/neo replicon. This result was also obtained with replicons expressing fusion proteins with progressively larger C-terminal deletions of CP (data not shown). Thus, the participation of CP in replicon RNA synthesis was unrelated to survival of transfected cells following drug selection. This result also indicated that membrane association of CP was necessary for enhanced cell survival during drug selection. Ilkow et al. (2011) recently showed that RUBV CP inhibited Baxmediated apoptosis in a number of cell lines, including Vero, and that the presence of the E2 signal sequence as well as five R residues immediately upstream from the E2 signal sequence were necessary for this inhibition. Reasoning that at least the greater survival during drug selection exhibited by RUBrep/C-GFP/neo-transfected cells in comparison to RUBrep/GFP/neo-transfected cells could be due to the antiapoptotic activity of CP, we constructed a C-GFP replicon containing substitutions of the five R residues with A (CR5A), a mutation that Ilkow et al. (2011) showed to eliminate the ability of CP to inhibit apoptosis ( Fig. 1A) . Consistent with our hypothesis, survival following drug selection of the cells transfected with the CR5A replicon was $ 9 fold lower than with the C-GFP replicon (data not shown). In the CR5A replicon-transfected cells following drug selection, the mutant CP-GFP fusion was detectably expressed in a high percentage of the cells in the culture ($88%) and exhibited a cytoplasmic distribution with a tendency to form cytoplasmic foci in contrast to the native CP ( Fig. 1C , particularly in boxed region). Following selection CR5A replicon-transfected cells exhibited the same growth properties as did the RUBrep/GFP/neo-transfected cells, ie slow growth and difficulty achieving confluence ( Fig. 1D ). Staining with antibodies for activated caspase-3 revealed no differences in the percentage of apoptotic cells among the three drug-selected cell lines (GFP, C-GFP, and CR5A-GFP) as $ 6% of the cells in all three cell lines exhibited activated caspase-3 (vs o1% in Vero cells).
Replicon stability following release from drug selection and IFN-a treatment
To determine if the replicons were stable in the culture in the absence of the antibiotic, transfected cultures that had been maintained in medium containing antibiotic were transferred to antibiotic-free medium and subsequently subcultured. When transfected cultures released from antibiotic selection were screened for the presence of replicon RNA by Northern blotting, RUBrep/GFP/neo RNA eventually became undetectable, but required twelve passes (Fig. 3) . In contrast, RUBrep/C-GFP/neo RNA was clearly detectable after twelve passes, although somewhat diminished in intensity in comparison with the culture prior to release from the antibiotic.
Vero cells lack the b-IFN gene, but maintain the Type I IFN receptor and thus are responsive to exogenously applied IFN. We found that pretreatment of Vero cells with 1000 IU of IFN-a reduces RUBV replication by tenfold (data not shown). To test the susceptibility of the replicon to IFN, RUBrep/C-GFP/neo-transfected cells were treated with increasing dosages of IFNÀ a.(50, 100, 500, and 1000 IU) for one week in drug free medium (RUBrep/GFP/neo cells were not used in these experiments because of their poor growth properties). The culture used for analysis had been maintained for 12 weeks and roughly 15% of the cells in the culture were positive for GFP. As a further test for presence of the replicon, a recently developed fluorescent in situ hybridization (FISH) assay (Matthews and Frey, 2011) was employed which showed that 15-18% of the cells in the culture contained detectable replicon RNA, demonstrating a correlation between RNA synthesis and GFP expression. As shown in Figs. 4A and B , IFN-a decreased the number of GFP and replicon positive cells as well as total GFP production (measured by Western blot) in a dose-dependent manner. RT-PCR was also used as a more sensitive assay to detect replicon RNA, but as shown in Fig. 4C , replicon RNA was still detectable, on day 6 post-treatment, albeit at a reduced level.
As there is still residual replicon RNA after one week of IFN-a treatment, we continued incubation of RUBrep/C-GFP/neo cells with 1000 IU of IFN-a for an additional four weeks, at which time the replicon was undetectable by RT-PCR (Fig. 5A ). To determine if the replicon had been eliminated, the cells which had been treated with IFN-a for five weeks were subcultured and either maintained or released from treatment. One week after subculture, the presence of replicon was monitored by RT-PCR and microscopically by FISH and GFP fluorescence. To our surprise, the replicon was restored after release from IFN treatment ( Fig. 5B  and C) . Particularly, as shown in Fig. 5C , the number of cells expressing GFP and positive for FISH was similar to control RUBrep/C-GFP/neo cells that had been maintained in parallel without IFN treatment. Taken together, these data indicate that while IFN-a suppresses replicon replication, it fails to cure the cells of the replicon. Fig. 3 . Replicon stability following drug release. RUBrep/GFP/neo and RUB/C-GFP/ neo-transfected Vero cells that had been selected and maintained in the presence of G418 for 12 weeks were transferred to medium without G418 and subcultured on a weekly basis. P0 refers to the last passage in the presence of drug while P1, P2, etc. refer to weekly passages 1, 2, etc. in absence of drug. A northern blot was performed to detect the presence of replicon-specific RNAs after the indicated passages.
Discussion
The strategy of engineering replicons expressing drug resistance markers for selection of cultures uniformly harboring the replicon has been used with a number of viruses and here we applied it to RUBV. Selection of drug-resistant cells following replicon transfection was readily achieved, as we had anticipated considering the relatively noncytopathic nature of RUBV. These cell lines have already been used in several studies on RUBV replication (Claus et al., 2007; Fontana et al., 2010; Fontana et al., 2007; Matthews et al., 2010) . The RUBV replicons used in this study were capable of expressing a protein in addition to the drug resistance factor and we used this capability to study the RUBV CP, a multifunctional protein with capacities exceeding formation of the virion core (Ilkow et al., 2010b) . We found that CP was necessary for maximal cell survival during drug selection and for growth equivalent to normal Vero cells following selection. In contrast, replicons of the flaviviruses Kunjin and West Nile virus in which the virion structural proteins were replaced with a drug resistance gene, drug selected cultures grew normally without apparent cytopathic effect (Khromykh and Westaway, 1997; Shi et al., 2002) . In the case of the alphaviruses, corresponding replicons of New World viruses such as western and Venezuelan equine encephalitis viruses (WEEV and VEEV) yielded drug selected cultures that were readily established without cytopathic effect (Garmashova et al., 2007) . However, replicons of Old World alphaviruses such as Sindbis virus (SINV) and Semliki Forest virus (SFV) required the selection of noncytopathic variants, mutations in which were used to construct replicons which efficiently generated drug selected cultures (Frolov et al., 1999; Perri et al., 2000) . This dichotomy among alphavirus replicons was based on cell transcriptional shutdown determinants residing in the CP of VEEV and WEEV (which was not included in the replicon) vs in nsP2 of SINV and SFV (in which the noncytopathic mutations occurred).
Inclusion of CP in the replicon specifically increased transfected cell survival during drug selection by almost tenfold and the resulting culture had a growth rate similar to Vero cells while cells transfected with the replicon lacking CP grew at a much slower rate and failed to reach confluency without heavy seeding. Considering the well described effect of CP on virus RNA synthesis Frey, 2003, 2005; Tzeng et al., 2006) , we initially hypothesized that CP enhanced replicon RNA synthesis and concomitantly neo R drug resistance marker production. However, we found SG RNA to be in similar abundance in cells transfected with both replicons, both before and after drug selection (replicons expressing CP produced more genomic RNA) as was the neo R protein. Furthermore, the entirety of CP, including the C-terminal E2 signal sequence, was needed for maximal survival during drug selection whereas only the N-terminal 88 aa is needed for CPmediated enhancement of replicon RNA synthesis. Recently, Ilkow et al. (2011) showed that CP exhibited inhibition of Bax-mediated induction of apoptosis and that five R residues in the C-terminal region of CP preceding the E2 signal sequence were necessary for this activity. Introduction of R to A substitutions of these five residues yielded a replicon that exhibited drug survival and resulting culture growth rate similar to the replicon without CP. Based on the studies of (Ilkow et al. (2011) , we conclude that the enhanced survival mediated by CP is due to its anti-apoptotic activity. The mechanism behind the effect of CP on the growth of the selected culture is not as obvious as these cultures did not exhibit the characteristics of apoptotic RUBV-infected cells, namely the presence of floating cells in the culture medium (Pugachev and Frey, 1998) , and shared an equivalent, low percentage of apoptotic cells as detected by activated caspase-3 assay (albeit higher than the control Vero cells). Thus, CP may have additional pro-growth effects on the cell that are mediated through these R residues. Another possibility is that CP, through these R residues, modulates the known cytopathogenicity determinants which reside on the P150 protein (see below), perhaps through its ability to bind to P150 (Tzeng et al., 2006) . As indicated by the lower percentage of cells detectably expressing GFP in the C-GFP replicon-transfected cultures in contrast to the GFP and CR5A-GFP replicon transfected cultures, there may also be a CP-mediated modulation of replicon gene expression, including putatively P150, the mechanism of which is unknown at this time.
Drug-selected, replicon-transfected cell lines have also been used to elucidate mutations in the replicon genome which impact the interaction of the replicon with the host cell. As described above, mutations in nsP2 of Old World alphaviruses were necessary to alter the cytopathogenicity of the replicon to allow for cell survival (Frolov et al., 1999; Perri et al., 2000) . In the case of Fig. 4 . Effect of IFN-a treatment on replicon stability. RUBrep/C-GFP/neo-transfected cells were subcultured in the absence of G418 and treated with 0, 50, 100, 500, or 1000 IU/ml of IFN-a on the second day after seeding. Control Vero and RUBrep/C-GFP/neo cells were maintained in the absence or presence of G418 as indicated. Six days post IFN treatment, cells were assayed for GFP fluorescence and by FISH for the presence of replicon RNA (Panel A). To quantify the percentage of positive cells, at least 200 cells from three different fields of view were counted. The bars are the means from three independent experiments and the error bars represent the standard deviation from the mean. Lysates of similarly treated parallel cultures were assayed for GFP by Western blot (Panel B). Total cell RNA extracted from control Vero cells or RUBrep/C-GFP/neo cells maintained in the presence of G418, the absence of G418, or the absence of G418 in the presence of 1000 IU/ml of IFN-a for six days and assayed by RT-PCR using primers specific for GFP, or b-actin (internal control) (Panel C). hepatitis C virus, mutations in the NS3, NS4a, and NS5b were frequently encountered which were necessary to optimize replication of the replicon [reviewed in (Woerz et al., 2009) ]. Mutations in the NS2A protein of Kunjin virus were found to affect the virus-induced inhibition of IFN-beta promoter-driven transcription (Liu et al., 2004) In this regard, the RUBV CP was needed for optimal cell survival and growth and we did not search for optimizing mutations in other regions of the replicon genome. However, for example, determinants of RUBV cytopathogenicity in cell culture have been mapped to the P150 gene, in particular, an opaque and clear plaque phenotype between variants of the same strain of RUBV (Pugachev et al., 1997) . The replicons used in this study were derived from the clear plaque variant and thus it is possible that mutations have been selected during passage of the replicon-selected cells that reduce cytopathogenicity and identification of such attenuating mutations could be used to specifically localize determinants of this phenotype.
We also used the drug-selected, replicon-transfected cultures to assess the stability of the replicon following drug withdrawal. This was of interest considering the capacity of RUBV for long-term persistent infection both in cell culture (Mifune et al., 1970; Stanwick and Hallum, 1974) and in vivo, particularly in congenitally infected infants (Lee and Bowden, 2000) . In cell culture, RUBV is able to readily persistent infections in all cell lines tested and analysis of replicon stability was done to gain insight into the innate ability of RUBV to persist at the cell level in the absence of infectious particles to renew the infection in cells in the culture that become cured. The replicons were stable, even in the RUBrep/GFP/neo-transfected cells which required 12 weeks for curing. We hypothesize that curing in this cell line occurs when a daughter cell fails to receive a replicon following cell division and, considering the relative growth advantage that a replicon-free cell would have over a cell harboring the RUBrep/GFP/neo replicon, the cured cells would take over this culture. In the case of the RUBrep/C-GFP/neo transfected culture in which the replicon-containing and free cells grow at equal rates, cured cells would not have this advantage. RUBV is able to persist in IFN-competent as well as IFN-deficient cell lines (such as Vero) and we thus tested the effect of exogenously applied IFN-a on replicon stability using the RUBrep/C-GFP/neo cell line. IFN-a has been shown to rapidly inhibit HCV replicon RNA replication in HCV replicon-stable cell lines and prolonged IFN-a treatment (4 passages) leads to curing the cultures of the replicon (Blight et al., 2002; Frese et al., 2001; Kato et al., 2003) . We found that IFN-a treatment rapidly downregulated replicon-specific RNA and protein synthesis and eventually eliminated evidence of the replicon, but five weeks were required. Then, surprisingly, the replicon reappeared within one week of suspension of IFN-a treatment. The detection limit of our RT-PCR assay is 1 pg of ss genomic replicon RNA, corresponding to 0.06 genomic copies per cell as 3X10 6 cells were used in the curing experiments shown in Fig. 5A . We suggest that the replicon persisted as dsRNA, which would be undetectable by RT-PCR as the GC content of the RUBV genome is $ 70%. Both Mifune et al. and Stanwick and Hallum (Mifune et al., 1970; Stanwick and Hallum, 1974) also found that treatment of RUBV-persistently infected Vero cells with IFN reduced virus replication and eliminated evidence of virus after $ 2-3 weeks as detected by infectious virus in the culture medium and RUBV-antigen expressing cells. In the Stanwick and Hallum study, however, cells remained cured of virus after release from IFN treatment. It is possible that the RUBrep/C-GFP/neotransfected cultures would be cured by additional IFN-a treatment, but this discrepancy with our finding may also be related to the type of IFN used. Both of these previous studies obtained IFN by induction of BSC1 cells, another African green monkey kidney cell line, by poly IC treatment while we used a recombinant IFN-a. Interestingly, Stanwick and Hallum found that other cells persistently infected with RUBV [BSC1, BHK (hamster)(these cells lack the type I IFN After five weeks of IFN-a treatment, the RUBrep/C-GFP/neo cells were subcultured and either maintained for a sixth week in the presence of IFN-a or released from IFN treatment by maintenance in normal medium (RLS). Control Vero and RUBrep/C-GFP/neo cells were maintained for a sixth week in the absence and presence of G418, respectively. Total cell RNA was extracted and assayed by RT-PCR using primers specific for GFP and b-actin (B) or cells were examined by fluorescence microscopy for GFP expression or FISH to detect the presence of replicon RNA (C0. Quantition was done as in Fig.4A (C) ). receptor), RK13 (rabbit), and HeLa (human)] were not cured by similar levels of exogenously applied IFN. In toto, RUBV persistent infection in cell culture is surprisingly refractory to IFN treatment, likely contributing to the ability of RUBV to establish a persistent infection.
Materials and methods
Cells, replicons, and drug selection
Vero cells were maintained in Dulbecco minimal essential medium (Invitrogen, Rockville, Md.) supplemented with 5% fetal bovine serum (FBS) and gentamicin (10 mg/ml; Invitrogen) while BHK cells were maintained in Dulbecco minimal essential medium supplemented with 10% FBS and gentamicin (10 mg/ml). The replicons used in the study, RUBrep/GFP/neo and RUBrep/C-GFP/ neo, have been previously described (Fontana et al., 2007) while RUBrep/C(-S)GFP/neo was constructed by substituting the corresponding fusion protein gene from RUBrep/C(1-277)GFP (Tzeng and Frey, 2003) into RUBrep/C-GFP/neo. The CR5A mutation, which substituted A's for R's as residues 264, 268, 271, 275, and 277 of CP (Ilkow et al., 2011) was introduced into RUBrep/C-GFP/ neo using previously described strategies (Tzeng and Frey, 2003) . RUBrep/GFP/pac and RUBrep/C-GFP/pac were generated by replacing the neo R gene with the puromycin acetylase gene [obtained from I. Frolov; ]. Following transfection with in vitro replicon transcripts as previously described (Tzeng and Frey, 2002) , drug selection was done using medium containing 1200 mg/ml of G418 or 2 mg/ml of puromycin. Following selection, the replicon transfected cells were maintained in medium containing the drugs at these respective concentrations. Cloned cells lines were derived from colonies with maximal GFP expression, however experiments were done on the uncloned population except where indicated. Cell cycle analysis was done using propidium iodine staining. Briefly, cells (5 Â 10 5 /ml) were harvested, fixed with ethanol for 10-15 min at À 20 1C and RNA was removed by addition of RNase A (10 mg/ml, Sigma). Cells were pelleted and resuspended in propidium iodide solution (2.5 mg/ ml, Sigma). The analysis was performed by using a FACScanto flow cytometer (Becton Dickinson) and the FACSDiva research software (Hofmann et al., 1999; Suzuki et al., 1997) .
To test the relative efficiency of cell survival following transfection and drug selection, a ''reverse plaque assay'' was utilized . Briefly, $ 90% confluent monolayers were transfected with equal amounts of in vitro replicon transcripts. Four days post-transfection, the cells were trypsinized, adjusted to equivalent cell concentrations, and a series of threefold dilution were made in medium. Equal aliquots of each dilution were plated in drug-containing medium and the cell density generated from each dilution was visualized by crystal violet staining 1-2 weeks post plating.
IFN-a treatment
To test the effect of IFN on replicon stability, RUBrep/C-GFP/ neo cells were incubated in medium containing ''Universal Type I IFN'', an IFN-a hybrid constructed from recombinant Human IFN-aA and Human IFN-a D (PBL Interferon Source).
Detection of virus-specific macromolecules
Northern blot of analysis of isolated total cell RNA and Western blot analysis of cell lysates were done as previously described (Tzeng et al., 2001) and (Tzeng et al., 2006) , respectively. Rabbit anti-neomycin phosphotransferase (neo R factor) were obtained from Upstate Biotechnology and used at a 1:500 dilution, rabbit anti-GFP antibodies were obtained from Clonetech and used at a 1:50 dilution while rabbit anti-GADPH antibodies were obtained from Abcam and used at a 1:5000 dilution. The FISH assay which is used to detect replicon RNA in individual cells was done as described in (Matthews and Frey, 2011) . Fluorescently labeled cells (GFP or FISH) were visualized using a Zeiss Axioplan microscope with epifluorescence capacity. RT-PCR was done using protocols described in (Pugachev et al., 1997) . Specifically, first strand cDNA synthesis was primed using downstream primers 5 0 -CTGAAGATCTTCATTACTTGTACAGCT-3 0 (GFP) amplification proceeding using the downstream primers and upstream primer 5 0 -ATATACTAGTATGGTGAGCAAGGGCG-3 0 (GFP).
